2-phenylbenzothiazole has been researched along with Acute Confusional Senile Dementia in 21 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 3 (14.29) | 29.6817 |
| 2010's | 15 (71.43) | 24.3611 |
| 2020's | 3 (14.29) | 2.80 |
| Authors | Studies |
|---|---|
| Candeias, E; Cardoso, SM; Chand, K; Chaves, S; Rajeshwari, R; Santos, MA | 1 |
| Debnath, ML; Klunk, WE; Lin, KS; Mason, NS; Mathis, CA; Pan, J | 1 |
| Ambure, P; Roy, K | 1 |
| Papadopoulos, M; Patsis, G; Pelecanou, M; Pirmettis, IC; Raptopoulou, C; Terzis, A; Tzanopoulou, S | 1 |
| Dolgova, NV; George, GN; Harris, HH; Kroll, T; Millhauser, GL; Pickering, IJ; Pushie, MJ; Roseman, G; Schilling, KM; Sokaras, D; Summers, KL | 1 |
| Cao, M; Feng, X; Wang, W; Wang, Z; Xiang, H; Yang, X | 1 |
| Ge, S; Guyatt, G; Lu, L; Tang, C; Wang, S; Wen, H; Xu, M; Xu, N; Yao, G; Zeng, J; Zhang, Y; Zheng, X | 1 |
| George, GN; Harris, HH; Millhauser, GL; Pickering, IJ; Roseman, GP; Sopasis, GJ; Summers, KL | 1 |
| Jenagaratnam, L; McShane, R; Sampson, EL | 2 |
| Adlard, PA; Barnham, KJ; Curtain, CC; Doble, PA; Hare, DJ; Hinds, MG; Kirby, N; Li, QX; Lind, M; Masters, CL; McColl, G; Mertens, HD; Pham, CL; Roberts, AM; Roberts, BR; Ryan, TM | 1 |
| Ames, D; Batsman, S; Blennow, K; Bush, AI; Harrison, J; Lannfelt, L; Masters, CL; Murdoch, R; Ritchie, CW; Targum, S; Wilson, J; Zetterberg, H | 1 |
| Bedo, J; Blennow, K; Bush, AI; Cummings, JL; Faux, NG; Gunn, A; Harrison, J; Herd, CM; Ingelsson, M; Lannfelt, L; Masters, CL; Rembach, A; Ritchie, CW; Tanzi, RE; Tsatsanis, A; Zetterberg, H | 1 |
| Shoji, M | 1 |
| Barnham, KJ; Kenche, VB | 1 |
| Adlard, PA; Bica, L; Bush, AI; Cappai, R; Crouch, PJ; Donnelly, PS; Filiz, G; Finkelstein, DI; Nurjono, M; White, AR | 1 |
| Adlard, PA; Barnham, KJ; Bush, AI; Cherny, RA; Crouch, PJ; Donnelly, PS; Greenough, MA; Hung, LW; Masters, CL; Mot, AI; Parker, SJ; Savva, MS; Volitakis, I; White, AR | 1 |
| Faller, P | 1 |
| Barnham, KJ; Bush, AI; Cherny, RA; Kenche, VB; Link, CD; Masters, CL; McColl, G; Pukala, TL; Roberts, BR; Roberts, CM; Ryan, TM | 1 |
| Doraiswamy, PM; Xiong, GL | 1 |
6 review(s) available for 2-phenylbenzothiazole and Acute Confusional Senile Dementia
| Article | Year |
|---|---|
Anti-Aβ agents for mild to moderate Alzheimer's disease: systematic review and meta-analysis.
Topics: Acitretin; Alanine; Alzheimer Disease; Amyloid beta-Peptides; Antibodies, Monoclonal, Humanized; Anxiety; Azepines; Clioquinol; Copper; Cyclic S-Oxides; Depression; Diarrhea; Exanthema; Fatigue; Flurbiprofen; Humans; Immunoglobulins, Intravenous; Inositol; Mental Status and Dementia Tests; Minimal Clinically Important Difference; Orotic Acid; Oxadiazoles; Severity of Illness Index; Sulfonamides; Syncope; Thiadiazines; Treatment Outcome; Vomiting | 2020 |
Metal protein attenuating compounds for the treatment of Alzheimer's dementia.
Topics: Aged; Alzheimer Disease; Amyloid beta-Peptides; Chelating Agents; Clioquinol; Humans; Randomized Controlled Trials as Topic | 2014 |
[Drug therapy for Alzheimer's disease].
Topics: Alzheimer Disease; Amyloid beta-Peptides; Anti-Inflammatory Agents, Non-Steroidal; Cholinesterase Inhibitors; Clioquinol; Drug Design; Excitatory Amino Acid Antagonists; Flurbiprofen; Indoles; Memantine; Meta-Analysis as Topic; Randomized Controlled Trials as Topic | 2010 |
Alzheimer's disease & metals: therapeutic opportunities.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Animals; Binding Sites; Cations; Clinical Trials as Topic; Clioquinol; Coordination Complexes; Copper; Humans; Oxidative Stress; Protein Binding; Synapses; Zinc | 2011 |
Metal protein attenuating compounds for the treatment of Alzheimer's dementia.
Topics: Aged; Alzheimer Disease; Chelating Agents; Clioquinol; Humans; Randomized Controlled Trials as Topic | 2012 |
Pharmacological strategies for the prevention of Alzheimer's disease.
Topics: Alzheimer Disease; Clioquinol; Drug Delivery Systems; Humans; Pharmaceutical Preparations | 2006 |
2 trial(s) available for 2-phenylbenzothiazole and Acute Confusional Senile Dementia
| Article | Year |
|---|---|
Safety, efficacy, and biomarker findings of PBT2 in targeting Abeta as a modifying therapy for Alzheimer's disease: a phase IIa, double-blind, randomised, placebo-controlled trial.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Amyloid beta-Peptides; Biomarkers; Brain; Clioquinol; Dose-Response Relationship, Drug; Double-Blind Method; Down-Regulation; Female; Humans; Ionophores; Male; Metals; Middle Aged; Peptide Fragments; Placebo Effect; Quinolines; Safety; Treatment Outcome | 2008 |
PBT2 rapidly improves cognition in Alzheimer's Disease: additional phase II analyses.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Area Under Curve; Australia; Clioquinol; Cognition Disorders; Copper; Dose-Response Relationship, Drug; Double-Blind Method; Executive Function; Humans; International Cooperation; Ionophores; Neuropsychological Tests; Peptide Fragments; ROC Curve; Superoxide Dismutase; Superoxide Dismutase-1; Sweden; tau Proteins | 2010 |
13 other study(ies) available for 2-phenylbenzothiazole and Acute Confusional Senile Dementia
| Article | Year |
|---|---|
New Multitarget Hybrids Bearing Tacrine and Phenylbenzothiazole Motifs as Potential Drug Candidates for Alzheimer's Disease.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Cell Line, Tumor; Cell Survival; Cholinesterase Inhibitors; Drug Design; Humans; Models, Molecular; Molecular Conformation; Molecular Structure; Protein Aggregates; Protein Aggregation, Pathological; Structure-Activity Relationship; Tacrine; Thiazoles | 2019 |
Design, synthesis and structure-activity relationship of rhenium 2-arylbenzothiazoles as β-amyloid plaque binding agents.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Coordination Complexes; Drug Design; Humans; Organotechnetium Compounds; Peptide Fragments; Protein Binding; Radiography; Rhenium; Structure-Activity Relationship; Thiazoles; Tomography, Emission-Computed, Single-Photon | 2013 |
Exploring structural requirements of imaging agents against Aβ plaques in Alzheimer's disease: a QSAR approach.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Molecular Structure; Quantitative Structure-Activity Relationship; Thiazoles; Tomography, Emission-Computed, Single-Photon | 2015 |
Oxorhenium(V) and oxotechnetium(V) [NN][S]3 complexes of 2-phenylbenzothiazole derivatives.
Topics: Alzheimer Disease; Cell Line, Tumor; Crystallography, X-Ray; Humans; Ligands; Magnetic Resonance Spectroscopy; Models, Molecular; Molecular Structure; Organometallic Compounds; Organotechnetium Compounds; Oxidation-Reduction; Phenols; Radiopharmaceuticals; Rhenium; Sensitivity and Specificity; Stereoisomerism; Sulfhydryl Compounds; Technetium; Thiazoles | 2006 |
Alzheimer's Drug PBT2 Interacts with the Amyloid β 1-42 Peptide Differently than Other 8-Hydroxyquinoline Chelating Drugs.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Chelating Agents; Clioquinol; Copper; Humans; Ions; Metals; Oxyquinoline; Peptide Fragments; Solvents; Zinc | 2022 |
WBQ5187, a Multitarget Directed Agent, Ameliorates Cognitive Impairment in a Transgenic Mouse Model of Alzheimer's Disease and Modulates Cerebral β-Amyloid, Gliosis, cAMP Levels, and Neurodegeneration.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Anesthetics, General; Animals; Benzofurans; Biological Availability; Blood-Brain Barrier; Brain Chemistry; Clioquinol; Cyclic AMP; Disease Models, Animal; Drug Evaluation, Preclinical; Gliosis; Hippocampus; Male; Maze Learning; Memory Disorders; Mice; Mice, Inbred C57BL; Mice, Transgenic; Nausea; Neuroprotective Agents; Phosphodiesterase 4 Inhibitors; Resorcinols; Second Messenger Systems; Vomiting | 2019 |
Copper(II) Binding to PBT2 Differs from That of Other 8-Hydroxyquinoline Chelators: Implications for the Treatment of Neurodegenerative Protein Misfolding Diseases.
Topics: Alzheimer Disease; Animals; Chelating Agents; Clioquinol; Coordination Complexes; Copper; Density Functional Theory; Humans; Ligands; Molecular Structure; Neuroprotective Agents; Proteostasis Deficiencies; X-Ray Absorption Spectroscopy | 2020 |
Can we reverse Alzheimer's? New approaches from Harvard offer hope.
Topics: Alzheimer Disease; Clioquinol; Cognition; Health Behavior; Humans; Mental Processes; Risk Reduction Behavior; Task Performance and Analysis | 2013 |
Stabilization of nontoxic Aβ-oligomers: insights into the mechanism of action of hydroxyquinolines in Alzheimer's disease.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Animals; Benzothiazoles; Biophysics; Caenorhabditis elegans; Cells, Cultured; Cerebral Cortex; Chromatography, Gel; Clioquinol; Enzyme-Linked Immunosorbent Assay; Humans; Hydroxyquinolines; Mice; Microscopy, Electron; Neurons; Peptide Fragments; Protein Binding; Scattering, Small Angle; Thiazoles | 2015 |
Metal ionophore treatment restores dendritic spine density and synaptic protein levels in a mouse model of Alzheimer's disease.
Topics: Alzheimer Disease; Animals; Cells, Cultured; Clioquinol; Dendritic Spines; Disease Models, Animal; Female; Hippocampus; Ionophores; Memory; Metals; Mice; Mice, Transgenic; Nerve Tissue Proteins; Neurites; Neurogenesis; Synapses | 2011 |
The Alzheimer's therapeutic PBT2 promotes amyloid-β degradation and GSK3 phosphorylation via a metal chaperone activity.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Blotting, Western; Calcineurin; Calcineurin Inhibitors; Caspase 3; Cell Line, Tumor; Clioquinol; Copper; Enzyme Inhibitors; Glycogen Synthase Kinase 3; Humans; Mass Spectrometry; Matrix Metalloproteinase 2; Metals; Molecular Chaperones; Peptide Hydrolases; Phosphorylation; Zinc | 2011 |
Copper in Alzheimer disease: too much, too little, or misplaced?
Topics: Alzheimer Disease; Animals; Brain; Clioquinol; Copper; Hepatolenticular Degeneration; Humans; Menkes Kinky Hair Syndrome | 2012 |
Utility of an improved model of amyloid-beta (Aβ₁₋₄₂) toxicity in Caenorhabditis elegans for drug screening for Alzheimer's disease.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Animals; Animals, Genetically Modified; Caenorhabditis elegans; Clioquinol; Disease Models, Animal; Drug Evaluation, Preclinical; Humans; Neuroprotective Agents | 2012 |